Good morning. Elizabeth Cooney here, filling in for Ed Silverman today. Coffee is brewed, news is being made, and we’re ready for another working week. Let’s get to it.

Compounding companies like Athenex (ATNX) and Imprimis Pharmaceuticals (IMMY) are emerging to meet demand for lower-priced medicines by custom-making drugs, the Wall Street Journal says. That’s sparking legal challenges from such traditional pharmaceutical companies as Allergan (AGN) and Endo Pharmaceuticals (ENDP) and pushback from federal health regulators. “If people start taking compounded drugs because of cost, instead of a generic or new drug, that would undermine the premarket approval system,” said Julie Dohm, the FDA senior science adviser for compounding.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I hope this undermines their entire price fixing scenario and forces them into fair pricing (and getting rid of evil pbms). We need true competition and transparency in drug prices. If a compounder can do it safely and cheaper, then it’s on the industry to adjust.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy